vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与Healthpeak Properties（DOC）财务数据对比。点击上方公司名可切换其他公司
Healthpeak Properties的季度营收约是BIOCRYST PHARMACEUTICALS INC的1.8倍（$719.4M vs $406.6M），Healthpeak Properties净利率更高（73.2% vs 60.5%，领先12.7%），BIOCRYST PHARMACEUTICALS INC同比增速更快（209.1% vs 3.1%），Healthpeak Properties自由现金流更多（$357.0M vs $291.2M），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（109.4% vs 8.9%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
Healthpeak Properties是美国医疗地产领域的房地产投资信托基金，核心投资范畴覆盖老年住宅、生命科学相关物业及医疗办公楼三类资产。公司2007年于马里兰州组建，总部设在科罗拉多州丹佛市，在尔湾、纳什维尔、旧金山均设有办事处，截至2019年12月31日共持有617处物业的权益。
BCRX vs DOC — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $406.6M | $719.4M |
| 净利润 | $245.8M | $114.0M |
| 毛利率 | 97.7% | — |
| 营业利润率 | 64.0% | 17.4% |
| 净利率 | 60.5% | 73.2% |
| 营收同比 | 209.1% | 3.1% |
| 净利润同比 | 1017.5% | 2406.4% |
| 每股收益（稀释后） | $1.13 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $406.6M | $719.4M | ||
| Q3 25 | $159.4M | $705.9M | ||
| Q2 25 | $163.4M | $694.3M | ||
| Q1 25 | $145.5M | $702.9M | ||
| Q4 24 | $131.5M | $698.0M | ||
| Q3 24 | $117.1M | $700.4M | ||
| Q2 24 | $109.3M | $695.5M | ||
| Q1 24 | $92.8M | $606.6M |
| Q4 25 | $245.8M | $114.0M | ||
| Q3 25 | $12.9M | $-117.1M | ||
| Q2 25 | $5.1M | $31.7M | ||
| Q1 25 | $32.0K | $42.8M | ||
| Q4 24 | $-26.8M | $4.5M | ||
| Q3 24 | $-14.0M | $85.9M | ||
| Q2 24 | $-12.7M | $146.0M | ||
| Q1 24 | $-35.4M | $6.7M |
| Q4 25 | 97.7% | — | ||
| Q3 25 | 98.6% | 58.6% | ||
| Q2 25 | 98.3% | 60.2% | ||
| Q1 25 | 96.9% | 61.1% | ||
| Q4 24 | 95.4% | 60.3% | ||
| Q3 24 | 97.3% | 60.0% | ||
| Q2 24 | 98.4% | 60.6% | ||
| Q1 24 | 98.6% | 59.8% |
| Q4 25 | 64.0% | 17.4% | ||
| Q3 25 | 18.6% | 9.2% | ||
| Q2 25 | 18.2% | 5.7% | ||
| Q1 25 | 14.6% | 7.7% | ||
| Q4 24 | -3.4% | -2.2% | ||
| Q3 24 | 6.6% | 14.1% | ||
| Q2 24 | 8.0% | 22.3% | ||
| Q1 24 | -15.6% | 3.7% |
| Q4 25 | 60.5% | 73.2% | ||
| Q3 25 | 8.1% | -16.6% | ||
| Q2 25 | 3.1% | 4.6% | ||
| Q1 25 | 0.0% | 6.1% | ||
| Q4 24 | -20.4% | 0.7% | ||
| Q3 24 | -12.0% | 12.3% | ||
| Q2 24 | -11.6% | 21.0% | ||
| Q1 24 | -38.1% | 1.1% |
| Q4 25 | $1.13 | $0.16 | ||
| Q3 25 | $0.06 | $-0.17 | ||
| Q2 25 | $0.02 | $0.05 | ||
| Q1 25 | $0.00 | $0.06 | ||
| Q4 24 | $-0.13 | $0.02 | ||
| Q3 24 | $-0.07 | $0.12 | ||
| Q2 24 | $-0.06 | $0.21 | ||
| Q1 24 | $-0.17 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $274.7M | $467.5M |
| 总债务越低越好 | — | $9.8B |
| 股东权益账面价值 | $-119.2M | $7.5B |
| 总资产 | $514.2M | $20.3B |
| 负债/权益比越低杠杆越低 | — | 1.31× |
8季度趋势，按日历期对齐
| Q4 25 | $274.7M | $467.5M | ||
| Q3 25 | $212.9M | $91.0M | ||
| Q2 25 | $260.0M | $89.4M | ||
| Q1 25 | $295.1M | $70.6M | ||
| Q4 24 | $320.9M | $119.8M | ||
| Q3 24 | $96.8M | $180.4M | ||
| Q2 24 | $78.4M | $106.9M | ||
| Q1 24 | $84.3M | $101.8M |
| Q4 25 | — | $9.8B | ||
| Q3 25 | — | $9.1B | ||
| Q2 25 | — | $9.0B | ||
| Q1 25 | — | $8.9B | ||
| Q4 24 | — | $8.7B | ||
| Q3 24 | — | $8.6B | ||
| Q2 24 | — | $8.6B | ||
| Q1 24 | — | $8.8B |
| Q4 25 | $-119.2M | $7.5B | ||
| Q3 25 | $-387.9M | $7.6B | ||
| Q2 25 | $-421.6M | $7.9B | ||
| Q1 25 | $-451.9M | $8.2B | ||
| Q4 24 | $-475.9M | $8.4B | ||
| Q3 24 | $-468.6M | $8.6B | ||
| Q2 24 | $-475.6M | $8.8B | ||
| Q1 24 | $-476.2M | $8.9B |
| Q4 25 | $514.2M | $20.3B | ||
| Q3 25 | $446.4M | $19.6B | ||
| Q2 25 | $457.2M | $19.8B | ||
| Q1 25 | $480.0M | $19.8B | ||
| Q4 24 | $490.4M | $19.9B | ||
| Q3 24 | $491.3M | $20.0B | ||
| Q2 24 | $472.4M | $20.2B | ||
| Q1 24 | $467.9M | $20.5B |
| Q4 25 | — | 1.31× | ||
| Q3 25 | — | 1.20× | ||
| Q2 25 | — | 1.14× | ||
| Q1 25 | — | 1.08× | ||
| Q4 24 | — | 1.04× | ||
| Q3 24 | — | 1.00× | ||
| Q2 24 | — | 0.98× | ||
| Q1 24 | — | 0.99× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $292.0M | $1.3B |
| 自由现金流经营现金流 - 资本支出 | $291.2M | $357.0M |
| 自由现金流率自由现金流/营收 | 71.6% | 49.6% |
| 资本支出强度资本支出/营收 | 0.2% | 124.4% |
| 现金转化率经营现金流/净利润 | 1.19× | 10.99× |
| 过去12个月自由现金流最近4个季度 | $344.9M | — |
8季度趋势，按日历期对齐
| Q4 25 | $292.0M | $1.3B | ||
| Q3 25 | $41.6M | $315.0M | ||
| Q2 25 | $41.3M | $363.5M | ||
| Q1 25 | $-27.5M | $279.4M | ||
| Q4 24 | $-5.2M | $1.1B | ||
| Q3 24 | $8.2M | $318.2M | ||
| Q2 24 | $-1.4M | $316.2M | ||
| Q1 24 | $-53.7M | $152.6M |
| Q4 25 | $291.2M | $357.0M | ||
| Q3 25 | $40.3M | — | ||
| Q2 25 | $41.1M | — | ||
| Q1 25 | $-27.7M | — | ||
| Q4 24 | $-5.9M | $333.7M | ||
| Q3 24 | $8.2M | — | ||
| Q2 24 | $-1.5M | — | ||
| Q1 24 | $-53.9M | — |
| Q4 25 | 71.6% | 49.6% | ||
| Q3 25 | 25.3% | — | ||
| Q2 25 | 25.2% | — | ||
| Q1 25 | -19.0% | — | ||
| Q4 24 | -4.5% | 47.8% | ||
| Q3 24 | 7.0% | — | ||
| Q2 24 | -1.4% | — | ||
| Q1 24 | -58.1% | — |
| Q4 25 | 0.2% | 124.4% | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.5% | 105.6% | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | 1.19× | 10.99× | ||
| Q3 25 | 3.23× | — | ||
| Q2 25 | 8.12× | 11.48× | ||
| Q1 25 | -859.91× | 6.52× | ||
| Q4 24 | — | 235.43× | ||
| Q3 24 | — | 3.71× | ||
| Q2 24 | — | 2.17× | ||
| Q1 24 | — | 22.85× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
